The French Endocrine Society suggests that the development of diabetes during ICIs treatment with anti-PD-1 or PD-L1 is not a contraindication for continued ICsI, but when the situation is severe, ICIs treatment can be delayed for a few days. Here, PDCD1 is linked to diabetes mellitus.